VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced a significant development milestone: its VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase and into the next stage of development. The announcement, made on August 6, 2026, marks the successful completion of the discovery portion of VERAXA's collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz).
With the discovery work completed, VERAXA will now focus on engineering the final bispecific ADC candidate and advancing preclinical validation. VXA-222 is not based on VERAXA's BiTAC platform, but it leverages the company's proprietary antibody engineering, linker, and conjugation technologies, making it one of its more advanced development programs.
This progress comes alongside an expansion of VERAXA's intellectual property portfolio. The company has filed its first BiTAC-related patent applications, as well as additional patents supporting conjugation chemistry, payloads, and antibody technologies. VERAXA now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047.
The advancement of VXA-222 and the strengthening of its IP portfolio underscore VERAXA's commitment to building a diversified oncology pipeline that spans bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers. This strategy positions the company to potentially address significant unmet medical needs in oncology.
For investors and industry observers, the milestone is important because it demonstrates VERAXA's ability to execute on its development plans and protect its innovations. The expansion of the patent portfolio provides a layer of protection for the company's proprietary technologies, which could be crucial for maintaining a competitive edge in the rapidly evolving field of cancer therapeutics.
However, as with all biotech companies, VERAXA faces risks and uncertainties. Forward-looking statements in the announcement are subject to various factors, including those detailed in the company's SEC filings. Investors are advised to consider these risks when evaluating the company's prospects.
The latest news and updates relating to VERAXA are available in the company's newsroom at https://ibn.fm/VRXA.
